Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sorrento Therapeutics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, indicating separate examination settings across the docket.
RAO, SAVITHA M is the busiest examiner, with 1 pending action. Counsel should use matter-specific prosecution strategies while coordinating broader portfolio objectives.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| CHATTIN, AMY MARIE | 1 | 72.2% | +45.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | HAMA, JOANNE | 104d overdue |
| 17830865 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | CHATTIN, AMY MARIE | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | HAMA, JOANNE | 104d overdue |
| 18561529 | Presurgical Perineural Administration of Resiniferatoxin For Reduction of Post-Operative Pain | RAO, SAVITHA M | 22d overdue |
| 17830865 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | CHATTIN, AMY MARIE | 26d |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1647 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18561529 | Presurgical Perineural Administration of Resiniferatoxin For Reduction of Post-Operative Pain | RAO, SAVITHA M | 1691 | §103 | Final Rejection | 22d overdue | Pending | Nov 16, 2023 |
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | HAMA, JOANNE | 1647 | §103§112 | Final Rejection | 104d overdue | Pending | Apr 06, 2023 |
| 17830865 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | CHATTIN, AMY MARIE | 1643 | §103§112 | Final Rejection | 26d | Pending | Jun 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSorrento Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Savitha M Rao has the most, with 1 of Sorrento Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
